Clinical Trial: A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07629258) titled 'A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors' on May 27.

Brief Summary: A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and hematological malignancies.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Tumors

Intervention: DRUG: GW01-200

GW01-200 tablets will be administered orally.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Groovy Medicine (Hangzhou) Ltd.

Disclaimer: Curated by HT Syndication....